Abstract
Nucleic acid based therapeutics offer the possibility of tailor-made treatment of malignant diseases. For recurrent glioblastoma multiforme (GBM), the most aggressive type of brain tumor, no accepted treatment exists, making therapeutically active nucleic acids a viable option. In this review, current preclinical and clinical studies harnessing the potential of antitumoral nucleic acids for GBM treatment will be considered. These include gene therapy to over-express antitumoral gene products, RNA interference to knock down components that promote tumor progression, and the tumor-targeted delivery of antitumoral double stranded RNA. Vectors applied in GBM for the delivery of nucleic acids will be discussed. These include non-replicating and replicating (oncolytic) viruses, as well as non-viral delivery vectors based on polycations or cationic lipids.
Keywords: Gene therapy, oncolytic virotherapy, poly IC, polyplexes, RNAi, Antisense RNA, RNA Interference, RNA polymerase, helicases, Oncolytic Viruses
Anti-Cancer Agents in Medicinal Chemistry
Title: Nucleic Acid-Based Therapeutics for Glioblastoma
Volume: 11 Issue: 8
Author(s): Alexei Shir, Alexander Levitzki, Ernst Wagner, Shoshana Klein and Manfred Ogris
Affiliation:
Keywords: Gene therapy, oncolytic virotherapy, poly IC, polyplexes, RNAi, Antisense RNA, RNA Interference, RNA polymerase, helicases, Oncolytic Viruses
Abstract: Nucleic acid based therapeutics offer the possibility of tailor-made treatment of malignant diseases. For recurrent glioblastoma multiforme (GBM), the most aggressive type of brain tumor, no accepted treatment exists, making therapeutically active nucleic acids a viable option. In this review, current preclinical and clinical studies harnessing the potential of antitumoral nucleic acids for GBM treatment will be considered. These include gene therapy to over-express antitumoral gene products, RNA interference to knock down components that promote tumor progression, and the tumor-targeted delivery of antitumoral double stranded RNA. Vectors applied in GBM for the delivery of nucleic acids will be discussed. These include non-replicating and replicating (oncolytic) viruses, as well as non-viral delivery vectors based on polycations or cationic lipids.
Export Options
About this article
Cite this article as:
Shir Alexei, Levitzki Alexander, Wagner Ernst, Klein Shoshana and Ogris Manfred, Nucleic Acid-Based Therapeutics for Glioblastoma, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (8) . https://dx.doi.org/10.2174/187152011797378599
DOI https://dx.doi.org/10.2174/187152011797378599 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Focus on the Use of Resveratrol as an Adjuvant in Glioblastoma Therapy
Current Pharmaceutical Design Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design Distinguished Photons: A Review of In Vivo Spectral Fluorescence Imaging in Small Animals
Current Pharmaceutical Biotechnology Editorial [Hot Topic: SOD Enzymes and Their Mimics in Cancer: Pro- vs Anti-Oxidative Mode of Action-Part I (Guest Editor: Ines Batinic-Haberle)]
Anti-Cancer Agents in Medicinal Chemistry [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology <sup>90</sup>Y-DOTA-Nimotuzumab: Synthesis of a Promising β− Radiopharmaceutical
Current Radiopharmaceuticals Monofunctional Platinum (PtII) Compounds – Shifting the Paradigm in Designing New Pt-based Anticancer Agents
Current Medicinal Chemistry Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets Heterologous Production of Death Ligands’ and Death Receptors’ Extracellular Domains: Structural Features and Efficient Systems
Protein & Peptide Letters Strategies for Preparing Different Types of Lipid Polymer Hybrid Nanoparticles in Targeted Tumor Therapy
Current Pharmaceutical Design Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects
Current Drug Metabolism Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Tracking Stem Cells for Cellular Therapy in Stroke
Current Pharmaceutical Design Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Review of and Perspectives on the Toxicology of Graphene-based Materials
Current Drug Metabolism